What is Demeetra?
Demeetra AgBio operates at the intersection of precision medicine and industrial biotechnology, specializing in proprietary gene-editing technologies such as Cas-CLOVER and the piggyBac transposase system. These integrated platforms are engineered to facilitate high-efficiency genome modifications, providing critical support for commercial bioprocessing and discovery research. By offering flexible licensing models and comprehensive technical support, the firm serves a diverse clientele ranging from research institutions to large-scale contract development and manufacturing organizations (CDMOs). Their focus on ensuring freedom to operate in biologics manufacturing distinguishes them as a key enabler for firms seeking to streamline product development cycles and enhance stable expression capabilities in complex biological systems.
How much funding has Demeetra raised?
Demeetra has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
Key Investors in Demeetra
PPP
Public-Private Partnership
What's next for Demeetra?
With the recent infusion of capital, Demeetra is poised to scale its operational capacity and deepen its market penetration. The strategic focus will likely shift toward expanding the adoption of its Cas-CLOVER platform, which offers a compelling alternative to traditional CRISPR-based methods by providing enhanced intellectual property security and precision. As the demand for sophisticated gene-editing tools continues to rise within the biopharma industry, Demeetra is expected to prioritize the development of new partnerships with CDMOs to integrate its technologies into standard manufacturing workflows. This phase of growth will be critical in transitioning the company from a technology provider to an essential infrastructure partner in the global biologics supply chain, ultimately driving long-term value for stakeholders and advancing the frontiers of genetic research.
See full Demeetra company page
